# Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

> **NCT02974621** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cediranib
- **DRUG:** Cediranib Maleate
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02974621
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-07
- **Primary completion:** 2022-12-31
- **Final completion:** 2026-07-17
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974621, "Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT02974621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*